Financial Performance - For the three months ended June 30, 2021, the company's consolidated revenue was approximately HKD 41,300,000, a decrease of about 0.2% compared to approximately HKD 41,400,000 for the same period last year[3]. - The loss attributable to the company's owners for the same period was approximately HKD 5,190,000, compared to a profit of approximately HKD 600,000 for the same period last year[6]. - The gross profit margin for the three months ended June 30, 2021, was approximately 56.4%, down from 61.5% in the same period last year[7]. - Operating expenses for the period were approximately HKD 28,070,000, compared to HKD 27,584,000 in the previous year, indicating an increase of about 1.8%[7]. - The company reported a total comprehensive loss of approximately HKD 5,961,000 for the period, compared to a total comprehensive income of HKD 790,000 for the same period last year[9]. - The basic loss per share for the period was HKD 0.12, compared to earnings per share of HKD 0.01 for the same period last year[7]. - The company experienced a foreign exchange loss of approximately HKD 771,000 during the period[9]. - The total comprehensive income attributable to non-controlling interests was HKD 2,000, compared to HKD 19,000 in the previous year[9]. - The group recorded revenue of approximately HKD 41.3 million for the reporting period, a decrease of about 0.2% compared to HKD 41.4 million in the previous year[35]. - The group reported a loss attributable to owners of approximately HKD 5.2 million, compared to a profit of HKD 600,000 in the same period last year, primarily due to a decrease in other income and an increase in operating expenses[35]. - The gross profit margin decreased to approximately 56.5% from 61.4% in the previous year, mainly due to rising ingredient costs[35]. - Operating expenses increased by approximately 1.8% to about HKD 28.1 million, driven by the costs associated with developing the new healthcare business[36]. Corporate Governance - The board of directors confirmed that the financial report is accurate and complete, with no misleading or fraudulent elements[2]. - The company has established an audit committee to review financial reports and internal control procedures, consisting of three independent non-executive directors[52]. - The company has adopted a code of conduct for directors' securities trading, ensuring compliance with GEM listing rules[53]. - The company is committed to maintaining high standards of corporate governance and has adhered to the corporate governance code during the reporting period[54]. - The executive directors are Mr. Huang Chao and Mr. Wu Xiaowen, with independent non-executive directors including Mr. Chen Yiping, Mr. Yang Haiyu, and Mr. Zeng Shiquan[55]. - The chairman of the board is Mr. Huang Chao[56]. Future Outlook and Strategic Plans - The company’s financial performance reflects ongoing challenges in the market, necessitating strategic adjustments moving forward[12]. - The group plans to accelerate the expansion of the Italian Tomato network, which currently has 6 cafes and 23 cake shops in Hong Kong[29]. - The group completed the acquisition of 70% of Huayin Biotechnology in May 2021, which has begun generating revenue from its skincare products[30]. - The healthcare market in China is expected to reach RMB 198 billion by 2026, growing tenfold since 2016, indicating significant growth potential for the group[33]. - The group anticipates improved business performance in the second half of the year as the economy develops, supported by government relief measures[32]. - The group will continue to invest in digitalization and optimize its self-developed ordering platform to capture growth opportunities in the takeaway sector[32]. - The outlook for the electronic cigarette business remains uncertain due to increased regulatory scrutiny from Chinese authorities[30]. Financial Position - The company has no interim dividend recommended for the three months ended June 30, 2021, consistent with no dividend in the same period last year[20]. - The net current liabilities and net liabilities as of June 30, 2021, were approximately HKD 115,974,000 and HKD 91,514,000, respectively[14]. - The repayment date for other loans amounting to approximately HKD 109,801,000 has been extended from June 22, 2021, to June 22, 2022[14]. - The company expects to have sufficient financial resources to repay its financial liabilities as they fall due in the foreseeable future[14]. Market Insights - The global trade is projected to reach USD 6.6 trillion in the second quarter of 2021, reflecting a 31% increase from the lowest levels in 2020[22]. - In China, the GDP grew by 7.9% year-on-year in the second quarter of 2021, driven by increased exports and the easing of lockdown measures[23]. - The total revenue of local restaurants in Hong Kong for the second quarter of 2021 was HKD 23.3 billion, an increase of 9.9% year-on-year[25]. - The online food delivery service market is expected to grow from USD 115.07 billion in 2020 to USD 126.91 billion in 2021, representing a growth of 10.3%[25]. Shareholder Information - As of June 30, 2021, the total number of issued ordinary shares was 4,166,175,000[43]. - Hanbo Holdings Limited holds 2,375,096,529 shares, representing approximately 57.01% of the total[41]. - Mr. Tang Shengming holds convertible bonds with an outstanding principal amount of HKD 40,000,000, which can be converted into 571,428,571 ordinary shares, equating to about 13.72% of the issued share capital[42]. - Ms. He Mingyi, as the spouse of Mr. Tang Shengming, is deemed to have the same number of shares as Mr. Tang, totaling 571,428,571 shares[42]. - No options were granted during the reporting period, and there were no unexercised options as of June 30, 2020[49].
荣晖控股(08213) - 2022 Q1 - 季度财报